[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-459891-105":59,"doc-detail-459891-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mesenchymal-stromal-cells-for-the-treatment-of-discogenic-low-back-pain-a-systematic-review-of-clinical-studies","Mesenchymal Stromal Cells for the Treatment of Discogenic Low Back Pain - A Systematic Review of Clinical Studies","","Mesenchymal stromal cell (MSC) therapy for chronic discogenic low back pain (LBP) was evaluated for efficacy and safety through a systematic literature search of PubMed/Medline, Scopus, Cochrane, and ClinicalTrials.gov under PRISMA guidelines. Eligible evidence included intradiscal MSC injections from published and ongoing clinical trials in patients unresponsive to conservative care, with risk-of-bias assessed using MINORS and RoB 2. Across 10 published studies (n=736) and eight ongoing trials (n=498), outcomes suggested modest improvements in pain and disability with occasional MRI findings of disc hydration and stabilization.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mesenchymal-stromal-cells-for-the-treatment-of-discogenic-low-back-pain-a-systematic-review-of-clinical-studies/459891/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mesenchymal-stromal-cells-for-the-treatment-of-discogenic-low-back-pain-a-systematic-review-of-clinical-studies/459891.png","ImageObject",300,407,{"name":92,"@type":93},"Stanley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the objective of this systematic review?","Question",{"text":112,"@type":113},"To elucidate the efficacy and safety of mesenchymal stromal cell (MSC) therapy for chronic discogenic low back pain that does not respond to conservative treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which databases and guidelines were used to identify relevant studies?",{"text":117,"@type":113},"A systematic search was conducted in PubMed/Medline, Scopus, Cochrane, and ClinicalTrials.gov following PRISMA guidelines.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes did the review report for MSC therapy?",{"text":121,"@type":113},"Across published and ongoing trials, visual analogue scale, Oswestry Disability Index, and quality-of-life questionnaires indicated modest improvements in pain, disability, and function, with occasional MRI evidence of increased disc hydration and stabilization or Pfirrmann grade improvement.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},459891,1791282097,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336477405376,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Neurospine 2025;22(4):998-1011. [https://doi.org/10.14245/ns.2551046.523](https://doi.org/10.14245/ns.2551046.523)  \nNeurospine  \npISSN 2586-6583 eISSN 2586-6591  \nReview Article  \nCorresponding Author  \nFabrizio Russo  \n [https://orcid.org/0000-0002-8566-8952](https://orcid.org/0000-0002-8566-8952)  \nOperative Research Unit of Orthopaedic and Trauma Surgery, Fondazione Policlinico Universitario Campus  \nBio-Medico, Via Alvaro del Portillo, 200–00128 Rome, Italy  \nEmail: [fabrizio.russo@policlinicocampus.it](fabrizio.russo@policlinicocampus.it)  \nReceived: July 15, 2025  \nRevised: November 5, 2025  \nAccepted: November 13, 2025  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://creativecom](https://creativecom)[mons.org/licenses/by-nc/4.0/](mons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nCopyright © 2025 by the Korean Spinal Neurosurgery Society  \nMesenchymal Stromal Cells for the Treatment of Discogenic Low Back Pain: A Systematic Review of Clinical Studies  \nGianluca Vadalà1,2, Fabrizio Russo1,2, Giuseppe Francesco Papalia2,3,  \nLuca Ambrosio1,2, Maria Tucci4, Giorgia Petrucci1, Inbo Han5, Rocco Papalia1,2, Vincenzo Denaro1  \n1Operative Research Unit of Orthopaedic and Trauma Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy  \n2Research Unit of Orthopaedic and Trauma Surgery, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy  \n3Oncological Orthopaedics Department, IFO-IRCCS Regina Elena National Cancer Institute, Rome, Italy 4Orthopaedic & Trauma Unit, Department of Translational Biomedicine and Neuroscience (DiBraiN), School of Medicine, University of Bari Aldo Moro, AOU Consorziale \"Policlinico”, Bari, Italy  \n5Department of Neurosurgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea  \nThis study aimed to elucidate the efficacy and safety of mesenchymal stromal cell (MSC) therapy for chronic discogenic low back pain (LBP) . A systematic literature search was conducted on PubMed/Medline, Scopus, Cochrane, and ClinicalTrials.gov following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analysis) guidelines . Eligible studies included published and ongoing clinical trials assessing intradiscal MSC injectionsin patients with chronic discogenic LBP unresponsive to conservative treatment. Risk-of-bias (RoB) assessment was performed through MINORS (Methodological Index for Non-randomized Studies) and RoB 2 tools . Within-and between-group differences were expressed as means and 95% confidence intervals. Effect sizes were calculated through Cohen d and g. Data from 10 published clinical studies (n = 736; 470 in treatment and 266 in control groups) revealed a mean age of 41.5 years and an average follow-up of 21.6 (range, 6–72) months . Various MSC sources were employed, including autologous and allogeneic bone marrowderived MSCs and adipose-derived MSCs, with doses ranging from 6 × 10⁶ to over 50 × 10⁶ cells/disc. Visual analogue scale, Oswestry Disability Index, and quality-of-life questionnaires indicated modest improvements in pain, disability, and functional status . Additionally, magnetic resonance imaging assessments occasionally demonstrated increased disc hydration and stabilization or improvement of Pfirrmann grade. Data from 8 ongoing trials (n = 498 participants; 276 treatment, 222 control) with follow-up periods ranging 6–24 months further corroborate the feasibility and safety of MSC-based interventions. MSC therapy is a biologically-driven approach for managing chronic discogenic LBP. While preliminary data support its potential to alleviate pain and improve disc integrity, further high-quality, standardized trials are necessary to optimize treatment protocols and confirm long-term clinical benefits.  \nKeyw","cbCaib2u8yXjcswI","https://ap.wps.com/l/cbCaib2u8yXjcswI","pdf",640778,14,"English","# Introduction\n## Burden and causes of low back pain\n## Intervertebral disc degeneration and disc microenvironment\n# Methods and evidence sources\n## PRISMA-guided literature search\n## Eligibility criteria and ongoing trials\n## Risk-of-bias and effect size analysis\n# Results and outcomes\n## Published clinical studies and baseline characteristics\n## MSC sources, dosing, and follow-up\n## Clinical scales and imaging findings\n## Ongoing trials corroborating feasibility and safety\n# Conclusion","[{\"question\":\"What was the objective of this systematic review?\",\"answer\":\"To elucidate the efficacy and safety of mesenchymal stromal cell (MSC) therapy for chronic discogenic low back pain that does not respond to conservative treatment.\"},{\"question\":\"Which databases and guidelines were used to identify relevant studies?\",\"answer\":\"A systematic search was conducted in PubMed/Medline, Scopus, Cochrane, and ClinicalTrials.gov following PRISMA guidelines.\"},{\"question\":\"What outcomes did the review report for MSC therapy?\",\"answer\":\"Across published and ongoing trials, visual analogue scale, Oswestry Disability Index, and quality-of-life questionnaires indicated modest improvements in pain, disability, and function, with occasional MRI evidence of increased disc hydration and stabilization or Pfirrmann grade improvement.\"}]","Mesenchymal Stromal Cells for the Treatment of Discogenic Low Back Pain - A Systematic Review of Clinical Studies | PDF",1790757195,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/0f2907d80ce4afd3a8f09fa4c4ec3ad0.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/852dfb702a9abe530cfb190ad2e3d9f1.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/eb6f240e2d3924432616335f47a98a58.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/13966ae998bc0dd3ac7a75e1c31702c9.webp",980,1306]